Search hospitals > California > Santa Monica

UCLA Hematology Oncology - Santa Monica

Claim this profile
Santa Monica, California 90404
Global Leader in Non-Small Cell Lung Cancer
Global Leader in Breast Cancer
Conducts research for Solid Tumors
Conducts research for Skin Cancer
Conducts research for Lung Cancer
91 reported clinical trials
8 medical researchers
Photo of UCLA Hematology Oncology - Santa Monica in Santa MonicaPhoto of UCLA Hematology Oncology - Santa Monica in Santa MonicaPhoto of UCLA Hematology Oncology - Santa Monica in Santa Monica

Summary

UCLA Hematology Oncology - Santa Monica is a medical facility located in Santa Monica, California. This center is recognized for care of Non-Small Cell Lung Cancer, Breast Cancer, Solid Tumors, Skin Cancer, Lung Cancer and other specialties. UCLA Hematology Oncology - Santa Monica is involved with conducting 91 clinical trials across 94 conditions. There are 8 research doctors associated with this hospital, such as Zev A. Wainberg, Sara Hurvitz, MD, Jonathan W. Goldman, and Saeed Sadeghi.

Area of expertise

1Non-Small Cell Lung Cancer
Global Leader
UCLA Hematology Oncology - Santa Monica has run 24 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
EGFR
2Breast Cancer
Global Leader
UCLA Hematology Oncology - Santa Monica has run 24 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at UCLA Hematology Oncology - Santa Monica

Non-Small Cell Lung Cancer
Breast Cancer
Lung Cancer
Skin Cancer
Solid Tumors
Pancreatic Cancer
Uterine Tumors
Prostate Cancer
Multiple Myeloma
Colorectal Cancer
Image of trial facility.

MK-2870

for Non-Small Cell Lung Cancer

The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14 skipping mutations, RET rearrangements, or less common EGFR point mutations of exon 20 S768I, exon 21 L861Q, or exon 18 G719X mutations. The primary hypotheses are that sacituzumab tirumotecan is: (1) superior to chemotherapy with respect to progression-free survival (PFS) per RECIST 1.1 as assessed by BICR in NSCLC with EGFR mutations; and (2) superior to chemotherapy with respect to overall survival (OS) in NSCLC with EGFR mutations.
Recruiting2 awards Phase 39 criteria
Image of trial facility.

Nivolumab + Relatlimab vs Pembrolizumab with Chemotherapy

for Lung Cancer

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%
Recruiting2 awards Phase 33 criteria
Image of trial facility.

CoREST Inhibitor + Anti-PD-1 Therapy

for Solid Cancers

This trial is testing a new drug, TNG260, combined with an existing cancer treatment, pembrolizumab, in patients with advanced solid tumors that have an STK11 mutation. TNG260 aims to block proteins that help cancer grow, while pembrolizumab boosts the immune system to fight the cancer. Pembrolizumab has been shown to be an effective and safe therapeutic option for various advanced cancers, including endometrial cancer and melanoma. The study will determine the best dose, safety, and effectiveness of this combination.
Recruiting1 award Phase 1 & 2

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at UCLA Hematology Oncology - Santa Monica?
UCLA Hematology Oncology - Santa Monica is a medical facility located in Santa Monica, California. This center is recognized for care of Non-Small Cell Lung Cancer, Breast Cancer, Solid Tumors, Skin Cancer, Lung Cancer and other specialties. UCLA Hematology Oncology - Santa Monica is involved with conducting 91 clinical trials across 94 conditions. There are 8 research doctors associated with this hospital, such as Zev A. Wainberg, Sara Hurvitz, MD, Jonathan W. Goldman, and Saeed Sadeghi.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security